Movement at Pfizer, Solvay and Biovail – People on the move

By Nick Taylor

- Last updated on GMT

Related tags: Senior vice president, Central nervous system, Medicine, Nervous system

in-PharmaTechnologist presents its latest round up of appointments in the pharmaceutical industry, including movement at Pfizer, Solvay and Biovail.

Pfizer​ has appointed Martine George​ to the post of vice president of medical affairs of its oncology business, which involves managing relationships with cancer agencies, organisations and specialists.

Prior to joining Pfizer George worked at GPC Biotech as senior vice president of drug development and has also held posts at Sandoz, Johnson & Johnson and Ortho Biotech during her 20 years in the pharmaceutical industry.

Barry Hayter​ has been appointed general manager of Solvay Pharma’s​ Canadian operations, succeeding Graham Jobson who has taken the post of human resources manager in commercial operations in Hanover, Germany.

Hayter was previously senior area director for Solvay in South and South East Asian countries and has worked in the pharmaceutical industry since 1983.

Vantia Therapeutics ​has appointed Rachel Morten​ as head of regulatory affairs. Morten has 24 years experience in regulatory affairs as an independent consultant and at companies including Averion and ChapelPharma.

Biovail Corporation​ has made two new appointments, with Rochelle Seide​ taking the post of vice-president, intellectual property of Biovail Laboratories International SRL​ and Fred Nicklas​ becoming vice-president, US commercial operations of BTA Pharmaceuticals​.

Seide has worked for 23 years as a patent attorney, predominantly in the life sciences industry, at law firms such as Schwegman, Lundberg & Woessner and is a board member of BioJudiciary Project, a not-for-profit venture set up by the Biotechnology Industry Organization (BIO).

Nicklas will take responsibility for sales, marketing and managed care efforts for BTA’s products. He has worked in this area for 20 years, gaining expertise of central nervous system (CNS) disorders, at companies including Valeant Pharmaceuticals and AstraZeneca, where he was director of brand communications for Seroquel (quetiapine).

Related topics: Markets & Regulations

Related news

Show more

Follow us

Products

View more

Webinars